A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG: Seladelpar
DRUG: Placebo to match Seladelpar

Sponsor

Gilead Sciences